Dr. Reddy's plots new assault on U.S. market

Indian drugmaker Dr. Reddy's Laboratories plans to launch about seven new generics in the United States this year and next, including its version of AstraZeneca's reflux drug Prilosec, a company official said in an interview with Reuters. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.